Please assess the completion status of the following clinical trial:

Trial Title: Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or greater~* Moderate to severe CKD not requiring dialysis (eGFR 15 - 45 ml/min/1.73 m2 by CKD-EPI)~* Absolute iron deficiency (serum ferritin \<300ng/ml and Transferrin Saturation \< 30%)~Exclusion Criteria:~* Hemoglobin concentrations \> 13 g/dL~* Known disorder of iron homeostasis (e.g., hemochromatosis)~* Known gastrointestinal disorder (irritable bowel disease, inflammatory bowel disease)~* Known liver disease (ALT/AST or bilirubin \> 3x normal)~* Serum phosphorus concentrations \< 3.0 mg/dL~* Any known cause of anemia other than iron deficiency or CKD (e.g., sickle cell anemia)~* Symptomatic gastrointestinal bleeding within 12 weeks prior to the screening visit.~* Subjects receiving any form of renal replacement therapy including hemodialysis, peritoneal dialysis, or renal transplant.~* Pregnancy or lactation in female participants~* Severe anemia defined as a hemoglobin \< 8.0 g/dL for males or a hemoglobin \<7.0 g/dL for females.~* Receipt of erythropoiesis stimulating agents within 4 weeks of screening.~* Receipt of intravenous iron therapy within 8 weeks of screening.~* Blood transfusion within 4 weeks of screening~* Known allergies or severe adverse reactions to previous oral iron therapy~* Current use of oral phosphorus binders.~* Current use of an active vitamin D analog

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ferric citrate (Type: EXPERIMENTAL): Participants randomized to the ferric citrate arm will receive 2 grams of ferric citrate three times a day with each meal.
- ferrous sulfate (Type: ACTIVE_COMPARATOR): Participants randomized to the ferrous sulfate arm will receive 325 mg of ferrous sulfate three times a day

Based on this trial design, predict the completion outcome and termination type (if applicable).